Survival analysis of breast cancer patients luminal subtype B on lymphovascular invasion (LVI), tumor-infiltrating lymphocyte (TIL), and expression of mammaglobin A

I Wayan Sudarsa; Nyoman Diwiya Abdi Nuratna

doi:10.15562/bmj.v12i2.4381

Survival analysis of breast cancer patients luminal subtype B on lymphovascular invasion (LVI), tumor-infiltrating lymphocyte (TIL), and expression of mammaglobin A

I Wayan Sudarsa ,

Nyoman Diwiya ,

pdf |
DOI: https://doi.org/10.15562/bmj.v12i2.4381 |
Published: 2023-04-12

Abstract

Background: With 1 in 10 women receiving a new cancer diagnosis each year, breast cancer is the most frequent cancer among women. Luminal B breast cancer incidence rates are rising in non-Hispanic white women aged 55 to 69 in Asia/Pacific and Indonesia subtype across all age groups. In Bali, Luminal B is the most prevalent subtype with the greatest fatality rate. This study aims to prove the survival analysis of Luminal B subtype breast cancer patients based on lymphovascular invasion (LVI), tumor-infiltrating lymphocyte (TIL), and mammaglobin A expression.

Methods: This study is a survival analysis using nested and prospective cohort methods. Retrospective data were taken from the Cancer Registry and Medical Records (MR) of patients in Sanglah General Hospital, mammaglobin results (Paraffin block test) on anatomical pathology analysis. Statistical Kaplan Meier and Cox Proportional hazard calculations performed with the SPSS program were significant (p<0.05).

Results: The number of research subjects was 60, with 32 subjects dying and 28 still alive until the data collection was completed. There was no difference in age between the two groups. The mean of all ages is 50.12 ± 9.93 years. Positive LVI has 9 months median survival (95% CI 8-10) with p= 0.013 risk 2,797 times. TIL high (positive 2- positive 3) median survival 8 months (95% CI 6.3-9.7) with p=0.003 and risk 3,151 times. Strong expression of mammaglobin A (3-4) had a median survival of 12 months (95% CI 4.4-19.5 months; p=0.015) and risk 3.34 times.

Conclusion: LVI, TIL, and mammaglobin A expression significantly affected poor survival in the breast cancer Luminal B subtype.

References

Ekassiana PMK, Supadmanaba IGP, Wihandani DM, Adiputra PAT. The association between Caveolin-1 expressions with clinicopathological characteristic of breast cancer. Bali Med J. 2019;8(3 SE-ORIGINAL ARTICLE):S774–9. Available from: https://www.balimedicaljournal.org/index.php/bmj/article/view/1587
Wihandani DM, Adiputra PAT, Supadmanaba IGP. Low prevalence of Caveolin-1 oncogenic polymorphism G14713A and T29107A among breast cancer patient in Sanglah General Hospital. Bali Med J. 2017;6(3 SE-ORIGINAL ARTICLE):S109–12. Available from: https://www.balimedicaljournal.org/index.php/bmj/article/view/743
Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: Patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):65024–33.
Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016. JAMA Netw open. 2020;3(8):e2013226.
Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, García O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016;37(7):669–76.
Abubakar M, Sung H, Bcr D, Guida J, Tang TS, Pfeiffer RM, et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: Analysis of 3012 women from an indigenous Asian population. Breast Cancer Res. 2018;20(1):1–14.
Widiana IK, Irawan H. Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pacific J Cancer Care. 2020;5(4):281–5.
Marchetti A, Buttitta F, Bertacca G, Zavaglia K, Bevilacqua G, Angelucci D, et al. mRNA markers of breast cancer nodal metastases: Comparison between mammaglobin and carcinoembryonic antigen in 248 patients. J Pathol. 2001;195(2):186–90.
Leygue E, Snell L, Dotzlaw H, Hole K, Troup S, Hiller-Hitchcock T, et al. Mammaglobin, a potential marker of breast cancer nodal metastasis. J Pathol. 1999;189(1):28–33.
Li C, Zhang T. Human mammaglobin: A specific marker for breast cancer prognosis. J BUON. 2016;21(1):35–41.
Song YJ, Shin SH, Cho JS, Park MH, Yoon JH, Jegal YJ. The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer. J Breast Cancer. 2011;14(3):198–203.
Galon J, Angell HK, Bedognetti D, Marincola FM. The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity. 2013;39(1):11–26.
Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018;52:16–25.
Hu Y, Liu P, Wu D, Jiang Y. Prognostic role of plasma mammaglobin a expression in breast carcinoma patients: A meta-analysis. Onco Targets Ther. 2018;11:3245–55.
García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative breast cancer: The future of immune targeting. Clin Med Insights Oncol. 2016;10:31–9.
Abe N, Ohtake T, Saito K, Kumamoto K, Sugino T, Takenoshita S. Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2-40 monoclonal antibody in breast cancer. Fukushima J Med Sci. 2016;62(1):57–63.
Houvenaeghel G, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, et al. Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. ESMO Open. 2021;6(6):100316.
Aleskandarany MA, Sonbul SN, Mukherjee A, Rakha EA. Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. Pathobiology. 2015;82(3–4):113–23.
Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Viale G, Curigliano G. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer. Breast Cancer Res Treat. 2020;183(2):347–54.